(Q46095754)

English

A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatolo

scientific article published on 10 May 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatolo (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

8

object named as

Takao Koike

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

author name string

Akito Takamura

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Shintaro Hirata

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Hayato Nagasawa

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Hideto Kameda

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Yohei Seto

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Tatsuya Atsumi

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Makoto Dohi

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Nobuyuki Miyasaka

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Masayoshi Harigai

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

publication date

10 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Modern Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

23

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

297-303

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0658-1

21 January 2018

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0658-1

21 January 2018

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0658-1

21 January 2018

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0658-1

21 January 2018

Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0658-1

21 January 2018

Circulating KL-6 levels in patients with drug induced pneumonitis.

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0658-1

21 January 2018

Serum indicators for the diagnosis of pneumocystis pneumonia.

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0658-1

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0658-1

21 January 2018

Serum biomarkers in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0658-1

21 January 2018

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0658-1

21 January 2018

Identifiers

10.3109/S10165-012-0658-1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22572888

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46095754&oldid=1260499516"